Your browser doesn't support javascript.
loading
The Risk of Recurrence of Subacute Thyroiditis Is HLA-Dependent.
Stasiak, Magdalena; Tymoniuk, Boguslaw; Stasiak, Bartlomiej; Lewinski, Andrzej.
Afiliación
  • Stasiak M; Department of Endocrinology and Metabolic Diseases, Polish Mother's Memorial Hospital - Research Institute, 93-338 Lodz, Poland. mstasiak33@gmail.com.
  • Tymoniuk B; Department of Immunology, Rheumatology and Allergy, Medical University of Lodz, 92-213 Lodz, Poland. boguslaw.tymoniuk@umed.lodz.pl.
  • Stasiak B; Institute of Information Technology, Lodz University of Technology, 90-924 Lodz, Poland. bartlomiej.stasiak@p.lodz.pl.
  • Lewinski A; Department of Endocrinology and Metabolic Diseases, Polish Mother's Memorial Hospital - Research Institute, 93-338 Lodz, Poland. alewin@csk.umed.lodz.pl.
Int J Mol Sci ; 20(5)2019 Mar 03.
Article en En | MEDLINE | ID: mdl-30832406
The frequency of recurrence of subacute thyroiditis (SAT) is rather high, reaching 20⁻30%. The reason for SAT relapse is still unknown. Recently, we have demonstrated the association between SAT and the presence of HLA-B*18:01, DRB1*01, and C*04:01, apart from the previously known HLA-B*35. The aim of the present study was to evaluate the correlation between SAT-associated HLA haplotypes and the risk of SAT recurrence. HLA-A, -B, -C, -DQB1 and -DRB1 were genotyped using a next-generation sequencing method in 49 SAT patients. The patients were divided into the following HLA groups: 1. HLA-B*35 and/or HLA-C*04, but without any other of the analyzed antigens; 2. HLA-DRB1*01, regardless of the co-presence of HLA-B*35 or -C*04:01, but without HLA-B*18:01; 3. HLA-B18 only, without any other antigen; 4. HLA-B*18:01 plus -B*35, regardless of the presence of any other analyzed antigens. The recurrence rate was compared between the groups. The recurrence rate was significantly increased in patients with HLA-B*18:01 plus HLA-B*35. In conclusion, the risk of SAT recurrence was HLA-dependent and the determining factor was the co-presence of HLA-B*18:01 and -B*35. In such high-risk patients, the steroid treatment regimen should be intensified with a slower dose reduction.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tiroiditis Subaguda / Antígenos HLA Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Mol Sci Año: 2019 Tipo del documento: Article País de afiliación: Polonia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tiroiditis Subaguda / Antígenos HLA Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Mol Sci Año: 2019 Tipo del documento: Article País de afiliación: Polonia